Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL

Journal of Lipid Research

Volumn 48, Issue 11, 2007, Pages 2411-2418

  Buono, Chiara ^a   Li, Yifu ^a   Waldo, Stephen W ^a,b   Kruth, Howard S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Atherosclerosis; Cholesterol; Endocytosis

Indexed keywords

22 HYDROXYCHOLESTEROL; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; CIGLITAZONE; CLOFIBRATE; COLONY STIMULATING FACTOR 1; IODINE 125; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN; METHYL BETA CYCLODEXTRIN; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST;

ARTICLE; ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL MATURATION; CELL VACUOLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FOAM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIPID TRANSPORT; LIQUID; MACROPHAGE; MONOCYTE; PINOCYTOSIS; PRIORITY JOURNAL;

BETA-CYCLODEXTRINS; CLOFIBRATE; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PINOCYTOSIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES;

EID: 35848935410     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700170-JLR200     Document Type: Article

References (39)

1. Bobryshev, Y. V. 2006. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 37: 208-222.
2. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
3. Kunjathoor, V. V., M. Febbraio, E. A. Podrez, K. J. Moore, L. Andersson, S. Koehn, J. S. Rhee, R. Silverstein, H. F. Hoff, and M. W. Freeman. 2002. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J. Biol. Chem. 277: 49982-49988.
4. Steinberg, D. 1997. Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 95: 1062-1071.
5. Kruth, H. S., W. Huang, I. Ishii, and W. Y. Zhang. 2002. Macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 277: 34573-34580.
6. Kruth, H. S., N. L. Jones, W. Huang, B. Zhao, I. Ishii, J. Chang, C. A. Combs, D. Malide, and W. Y. Zhang. 2005. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell formation with native low density lipoprotein. J. Biol. Chem. 280: 2352-2360.
7. Zhao, B., Y. Li, C. Buono, S. W. Waldo, N. L. Jones, M. Mori, and H. S. Kruth. 2006. Constitutive receptor-independent low density lipoprotein uptake and cholesterol accumulation by macrophages differentiated from human monocytes with macrophage-colony-stimulating factor (M-CSF). J. Biol. Chem. 281: 15757-15762.
8. Amyere, M., M. Mettlen, P. Van Der Smissen, A. Platek, B. Payrastre, A. Veithen, and P. J. Courtoy. 2002. Origin, originality, functions, subversions and molecular signalling of macropinocytosis. Int. J. Med. Microbiol. 291: 487-494.
9. Swanson, J. A., and C. Watts. 1995. Macropinocytosis. Trends Cell Biol. 5: 424-428.
10. Ma, H. T., W. W. Lin, B. Zhao, W. T. Wu, W. Huang, Y. Li, N. L. Jones, and H. S. Kruth. 2006. Protein kinase C beta and delta isoenzymes mediate cholesterol accumulation in PMA-activated macrophages. Biochem. Biophys. Res. Commun. 349: 214-220.
11. Zelcer, N., and P. Tontonoz. 2006. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116: 607-614.
12. Joseph, S. B., E. McKilligin, L. Pei, M. A. Watson, A. R. Collins, B. A. Laffitte, M. Chen, G. Noh, J. Goodman, G. N. Hagger, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA. 99: 7604-7609.
13. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536: 6-11.
14. Levin, N., E. D. Bischoff, C. L. Daige, D. Thomas, C. T. Vu, R. A. Heyman, R. K. Tangirala, and I. G. Schulman. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25: 135-142.
15. Tangirala, R. K., E. D. Bischoff, S. B. Joseph, B. L. Wagner, R. Walczak, B. A. Laffitte, C. L. Daige, D. Thomas, R. A. Heyman, D. J. Mangelsdorf, et al. 2002. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA. 99: 11896-11901.
16. Mak, P. A., B. A. Laffitte, C. Desrumaux, S. B. Joseph, L. K. Curtiss, D. J. Mangelsdorf, P. Tontonoz, and P. A. Edwards. 2002. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors alpha and beta. J. Biol. Chem. 277: 31900-31908.
17. Chawla, A., W. A. Boisvert, C. H. Lee, B. A. Laffitte, Y. Barak, S. B. Joseph, D. Liao, L. Nagy, P. A. Edwards, L. K. Curtiss, et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7: 161-171.
18. Rigamonti, E., L. Helin, S. Lestavel, A. L. Mutka, M. Lepore, C. Fontaine, M. A. Bouhlel, S. Bultel, J. C. Fruchart, E. Ikonen, et al. 2005. Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ. Res. 97: 682-689.
19. Naik, S. U., X. Wang, J. S. Da Silva, M. Jaye, C. H. Macphee, M. P. Reilly, J. T. Billheimer, G. H. Rothblat, and D. J. Rader. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113: 90-97.
20. Cignarella, A., T. Engel, A. von Eckardstein, M. Kratz, S. Lorkowski, A. Lueken, G. Assmann, and P. Cullen. 2005. Pharmacological regulation of cholesterol efflux in human monocyte-derived macrophages in the absence of exogenous cholesterol acceptors. Atherosclerosis. 179: 229-236.
21. Li, A. C., C. J. Binder, A. Gutierrez, K. K. Brown, C. R. Plotkin, J. W. Pattison, A. F. Valledor, R. A. Davis, T. M. Willson, J. L. Witztum, et al. 2004. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 114: 1564-1576.
22. Sparrow, C. P., J. Baffic, M. H. Lam, E. G. Lund, A. D. Adams, X. Fu, N. Hayes, A. B. Jones, K. L. Macnaul, J. Ondeyka, et al. 2002. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. 277: 10021-10027.
23. Schwartz, K., R. M. Lawn, and D. P. Wade. 2000. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274: 794-802.
24. Venkateswaran, A., B. A. Laffitte, S. B. Joseph, P. A. Mak, D. C. Wilpitz, P. A. Edwards, and P. Tontonoz. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Natl. Acad. Sci. USA. 97: 12097-12102.
25. Laffitte, B. A., J. J. Repa, S. B. Joseph, D. C. Wilpitz, H. R. Kast, D. J. Mangelsdorf, and P. Tontonoz. 2001. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA. 98: 507-512.
26. Hashimoto, S., M. Yamada, K. Motoyoshi, and K. S. Akagawa. 1997. Enhancement of macrophage colony-stimulating factor-induced growth and differentiation of human monocytes by interleukin-10. Blood. 89: 315-321.
27. Goldstein, J. L., and M. S. Brown. 1974. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 249: 5153-5162.
28. Lowry, O. H., N. J. Rosebrough, and A. L. Farr. 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193: 265-275.
29. Grimmer, S., B. van Deurs, and K. Sandvig. 2002. Membrane ruffling and macropinocytosis in A431 cells require cholesterol. J. Cell Sci. 115: 2953-2962.
30. Kruth, H. S., S. I. Skarlatos, K. Lilly, J. Chang, and I. Ifrim. 1995. Sequestration of acetylated LDL and cholesterol crystals by human monocyte-derived macrophages. J. Cell Biol. 129: 133-145.
31. Akiyama, T. E., S. Sakai, G. Lambert, C. J. Nicol, K. Matsusue, S. Pimprale, Y. H. Lee, M. Ricote, C. K. Glass, H. B. Brewer, Jr., et al. 2002. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22: 2607-2619.
32. Goldstein, J. L., S. K. Basu, and M. S. Brown. 1983. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98: 241-260.
33. Mazzone, T., C. Lopez, and L. Bergstraesser. 1987. Modification of very low density lipoproteins leads to macrophage scavenger receptor uptake and cholesteryl ester deposition. Arteriosclerosis. 7: 191-196.
34. Leake, D. S., G. May, A. A. Soyombo, and M. H. Nasr-Esfahani. 1989. The effect of macrophage stimulation on the uptake of acetylated low-density lipoproteins. Biochim. Biophys. Acta. 1005: 196-200.
35. Li, A. C., and C. K. Glass. 2004. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45: 2161-2173.
36. Castrillo, A., and P. Tontonoz. 2004. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu. Rev. Cell Dev. Biol. 20: 455-480.
37. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58.
38. Sallusto, F., M. Cella, C. Danieli, and A. Lanzavecchia. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389-400.
39. Fu, X., J. G. Menke, Y. Chen, G. Zhou, K. L. MacNaul, S. D. Wright, C. P. Sparrow, and E. G. Lund. 2001. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276: 38378-38387.